secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001193125-22-296035
Event type: debt
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD extends debt maturity to Dec 31, 2022; pays $4.2M accrued interest and $750K fee
--------------------------------------------------------------------------------

- Amendment No. 17 extends Financing Agreement maturity to Dec 31, 2022, contingent on certain milestones.
- Minimum cash covenant set at $7.5M; amendment fee of $750,000 paid to lenders.
- Company paid approximately $4.2M in accrued and unpaid interest as of Nov 30, 2022.
- Board continues evaluating options to strengthen capital structure and maintain normal operations.
- Company faces going-concern risk if it cannot refinance or raise additional capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312522296035/0001193125-22-296035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312522296035/d404005d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-296035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer